文献速递前列腺癌

奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌患者的耐受性:3期PROpel试验的进一步结果

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
PubMed 文献 · Eur Urol Oncol · 2024-04-06

PROpel试验(NCT03732820)在17个国家126个中心随机双盲比较奥拉帕利联合阿比特龙与安慰剂联合阿比特龙一线治疗转移性去势抵抗性前列腺癌的安全性,数据截止2021年7月30日。奥拉帕利联合阿比特龙组最常见不良事件为贫血(46.0% vs 16.4%)、恶心(28.1% vs 12.6%)和疲乏(27.9% vs 18.9%),3级及以上贫血发生率为15.1% vs 3.3%。奥拉帕利联合阿比特龙具有可管理且可预测的安全性特征。

要点

  • 奥拉帕利联合阿比特龙组最常见不良事件为贫血(46.0% vs 16.4%)、恶心(28.1% vs 12.6%)和疲乏(27.9% vs 18.9%)。
  • 奥拉帕利联合阿比特龙组3级及以上贫血发生率为15.1%,安慰剂联合阿比特龙组为3.3%。
  • 奥拉帕利联合阿比特龙组因不良事件停药比例为13.8%,安慰剂联合阿比特龙组为7.8%。

核心结论

  • 奥拉帕利联合阿比特龙具有可管理且可预测的安全性特征。

研究设计与样本

  • 随机(1:1)、双盲、安慰剂对照试验,在17个国家126个中心开展(2018年10月至2020年1月)。
  • 患者为转移性去势抵抗性前列腺癌且未接受过针对转移性去势抵抗性前列腺癌的全身治疗。
  • 干预为奥拉帕利(300 mg 每日两次)或安慰剂联合阿比特龙(1000 mg 每日一次)加泼尼松/泼尼松龙(5 mg 每日两次)。
  • 安全性通过不良事件报告(不良事件通用术语标准 v4.03)评估并进行描述性分析,数据截止日期为2021年7月30日。

主要发现

  • 奥拉帕利联合阿比特龙组 vs 安慰剂联合阿比特龙组最常见不良事件(所有级别)为贫血(46.0% vs 16.4%)、恶心(28.1% vs 12.6%)和疲乏(27.9% vs 18.9%)。
  • 奥拉帕利联合阿比特龙组 vs 安慰剂联合阿比特龙组3级及以上贫血发生率为15.1% vs 3.3%。
  • 奥拉帕利联合阿比特龙组 vs 安慰剂联合阿比特龙组因不良事件停药比例为13.8% vs 7.8%,因贫血停药比例为3.8% vs 0.8%。
  • 奥拉帕利联合阿比特龙组 vs 安慰剂联合阿比特龙组静脉血栓栓塞事件(所有级别)为7.3% vs 3.3%,3级及以上为6.8% vs 2.0%,最常见为肺栓塞(6.5% vs 1.8%)。
  • 奥拉帕利联合阿比特龙组最常见不良事件的发生率在早期(2个月内)达峰,通常通过剂量调整或标准医疗实践进行管理。

临床怎么用

  • 奥拉帕利联合阿比特龙组最常见不良事件通常可通过支持治疗、短暂暂停奥拉帕利给药和/或降低奥拉帕利剂量进行管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PROpel study (NCT03732820) demonstrated a statistically significant progression-free survival benefit with olaparib plus abiraterone versus placebo plus abiraterone in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting, irrespective of homologous recombination repair mutation status. OBJECTIVE: We report additional safety analyses from PROpel to increase clinical understanding of the adverse-event (AE) profiles of olaparib plus abiraterone versus placebo plus abiraterone. DESIGN, SETTING, AND PARTICIPANTS: A randomised (1:1), double-blind, placebo-controlled trial was conducted at 126 centres in 17 countries (October 2018-January 2020). Patients had mCRPC and no prior systemic mCRPC treatment. INTERVENTION: Olaparib (300 mg bid) or placebo with abiraterone (1000 mg od) plus prednisone/prednisolone (5 mg bid). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The data cut-off date was July 30, 2021. Safety was assessed by AE reporting (Common Terminology Criteria for Adverse Events v4.03) and analysed descriptively. RESULTS AND LIMITATIONS: The most common AEs (all grades) for olaparib plus abiraterone versus placebo plus abiraterone were anaemia (46.0% vs 16.4%), nausea (28.1% vs 12.6%), and fatigue (27.9% vs 18.9%). Grade ≥3 anaemia occurred in 15.1% versus 3.3% of patients in the olaparib plus abiraterone versus placebo plus abiraterone arm. The incidences of the most common AEs for olaparib plus abiraterone peaked early, within 2 mo, and were managed typically by dose modifications or standard medical practice. Overall, 13.8% versus 7.8% of patients discontinued treatment with olaparib plus abiraterone versus placebo plus abiraterone because of an AE; 3.8% versus 0.8% of patients discontinued because of anaemia. More venous thromboembolism events were observed in the olaparib plus abiraterone arm (any grade, 7.3%; grade ≥3, 6.8%) than in the placebo plus abiraterone arm (any grade, 3.3%; grade ≥3, 2.0%), most commonly pulmonary embolism (6.5% vs 1.8% for olaparib plus abiraterone vs placebo plus abiraterone). CONCLUSIONS: Olaparib plus abiraterone has a manageable and predictable safety profile. PATIENT SUMMARY: The PROpel trial showed that in patients who had not received any previous treatment for metastatic castration-resistant prostate cancer, olaparib combined with abiraterone was more effective in delaying progression of the disease than abiraterone alone. Most side effects caused by combining olaparib with abiraterone could be managed with supportive care methods, by pausing olaparib administration for a short period of time and/or by reducing the dose of olaparib.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Saad F, Armstrong AJ, Oya M, et al. Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial. Eur Urol Oncol. 2024. PMID: 38582650. doi:10.1016/j.euo.2024.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。